Blog Post

EU trade in medical goods: why self-sufficiency is the wrong approach

As countries are struggling with the COVID-19 pandemic, shortages in medical equipment led to EU export controls and war-time like procurement of respirators. While the crisis is still unfolding, there is a debate on whether the EU is too reliant on global value chains for medical goods. Looking at the world market of medical goods for the EU, we argue that self-sufficiency is the wrong approach. Global medical markets are to the benefits of the EU and stockpiling and preparation are more effective in preparing for emergencies.

By: and Date: April 14, 2020 Topic: Global Economics & Governance

The European Union has enacted war-like procurement measures to counter shortages of personal protective equipment (PPE) during the COVID-19 crisis. Automotive and apparel companies are producing respirators and face masks, respectively. Meanwhile, countries are trying to prevent shortages of these goods, with Germany and France enacting export bans. The production of PPE in the EU is highly concentrated, with only the Czech Republic, France, Germany and Poland producing these goods on a large scale. To coordinate this response, the European Commission imposed EU-wide export controls. Questions are being asked about whether or not the EU should produce more of its own medical supplies beyond the current emergency procurement, and if it should reduce reliance on global supply chains. We argue that such measures should only be used in a limited way. As one of the largest producers of medical goods, the EU should avoid protectionism and should support global supply chains, with widespread research and production of medicine and medical equipment. Global markets for medical goods benefit the EU economically and also lead to knowledge sharing and specialisation that will help stem future epidemics. Stockpiling and preparation would have been a far more effective approach to prevent the shortages the EU is now experiencing, without any of the downside effects that domestic production requirements entail.

EU trade in medical goods

The EU is a net importer of COVID-19 related PPE. In 2019, it imported $17.6 billion worth of these goods and exported $12.1 billion. However, looking at the broader picture, the EU is one of the leaders in terms of trade in high-tech medical goods. Its share of global exports of such goods in 2017 was 29% – double the EU’s share of total global exports (15.2%). The EU is also a leading exporter of pharmaceutical goods and vaccines, representing nearly one third of world exports in both categories (Figure 1). For pharmaceutical goods, the EU tends to export standard products and import more advanced ones. This is related to the EU exporting many packaged medicines that are not considered high-tech (according to the United States Census Bureau), whereas the EU exports less high-tech vaccines. In medical equipment, the EU has a 26% share of world exports. In this category, its exports are more geared towards advanced goods, and its imports towards standard products (Figure 1  and Table 1).

In terms of EU trade in medical goods with its biggest partners, the US and China, there are major structural differences in the types of goods being traded. The EU and China sell one another similar shares of high-tech goods: around 40% of total medical goods trade between the two (Table 2). However, it is noticeable that the EU imports nearly no pharmaceutical goods from China, and that in exchanges of medical equipment, the EU tends to sell more advanced goods to China and import less technologically advanced goods. EU-US trade in medical goods is in gross value terms worth much more than the equivalent trade with China. The EU imports more high-tech medical goods from the US than it exports to the US (Table 3).

Buy local? 

As European governments experience shortages in procuring some medical goods, there are calls for an industrial policy that moves supply chains back to the EU. Emmanuel Macron wants “European and national sovereignty” and “full independence” in parts of the medical market. Some industry representatives go even further and call for “sanitary sovereignty”. We argue that such protectionist policies would hurt the EU more than it would gain. In parts of the market, local suppliers can be necessary to avoid shortages during an emergency, as currently. In these cases, domestic supply chains should be supported and protected. However, import-substitution policies should only be used carefully for specific products. The form the next epidemic will take is uncertain, while maintaining entire supply chains for a large number of products in the EU would be prohibitively expensive and could lead to major international tension. If the EU subsidised its pharmaceutical companies with the aim of moving entire supply chains of a larger number of goods into the EU, or required healthcare providers to procure medical goods only from EU suppliers, it would effectively close these markets to foreign producers. Some products, such as PPE, can be stockpiled, which makes domestic production less important. The question is more pressing for perishable medicines – goods for which the EU is already one of the largest exporters.

Global supply chains for non-high tech medicines support the development of pharmaceutical companies in emerging markets, leading to more research and skill spillovers, which will allow them to handle better the next pandemic. Modern medicine is highly complex, and there are substantial advantages from global sharing of research and development of drugs and equipment. This implies that there is also a substantial gain from global specialisation, instead of every country trying to cover every part of the medical goods market. Our trade data shows that as one of the most research-intensive regions in the world, the EU has a very strong position in this market. The EU is currently facing difficulties sourcing ‘low-technology’ medical supplies such as masks and protective equipment, but also more advanced products such as respirators. For the potential next stage of the pandemic, during which a vaccine should be administered to the population at mass scale, the situation might be more favourable to the EU because of its existing advantage in producing vaccines (the EU exports around 30% of all vaccines worldwide).

Therefore, we argue that while localisation of production for some specific goods might be necessary to prepare for pandemics, there are substantial advantages to keeping Europe’s markets for medical goods open. Therefore, the strategy should be targeted and should avoid protecting parts of the market where there is no need for local production. Healthcare in the EU already accounts for 10% of GDP, and these costs are likely to rise as Europe’s population continues to age. Production of goods in cheaper countries helps to manage these costs, and frees funds for other areas of healthcare, including pandemic preparation. Precautionary stockpiling of non-perishable medical goods and provision of intensive-care beds and medical testing facilities do not need local production, and would have gone a long way to alleviate the shortages currently experienced. A good example is Finland, where medical stockpiles help it to manage the current crisis. Stockpiling at European level, eg through rescEU and the European Civil Protection Mechanism, could create further efficiency gains and ensure that emergency supplies go to the regions most in need.


Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint. Anyone is free to republish and/or quote this post without prior consent. Please provide a full reference, clearly stating Bruegel and the relevant author as the source, and include a prominent hyperlink to the original post.

Read article Download PDF More on this topic More by this author
 

Policy Contribution

Why has COVID-19 hit different European Union economies so differently?

All European Union countries are undergoing severe output losses as a consequence of COVID-19, but some have been hurt more than others. Factors potentially influencing the degree of economic contraction include the severity of lockdown measures, the structure of national economies, public indebtedness, and the quality of governance in different countries. With the exception of public indebtedness, we find all these factors are significant to varying degrees.

By: André Sapir Topic: European Macroeconomics & Governance Date: September 22, 2020
Read article More on this topic More by this author
 

Opinion

Without good governance, the EU borrowing mechanism to boost the recovery could fail

The European Union recovery fund could greatly increase the stability of the bloc and its monetary union. But the fund needs clearer objectives, sustainable growth criteria and close monitoring so that spending achieves its goals and is free of corruption. In finalising the fund, the EU should take the time to design a strong governance mechanism.

By: Guntram B. Wolff Topic: European Macroeconomics & Governance Date: September 15, 2020
Read article More by this author
 

Parliamentary Testimony

Employment and COVID-19

Testimony before the Economic Affairs Committee at the House of Lords, British Parliament on Employment and COVID-19.

By: Guntram B. Wolff Topic: European Macroeconomics & Governance, Finance & Financial Regulation, Testimonies Date: September 9, 2020
Read about event
 

Past Event

Past Event

Bruegel Annual Meetings 2020 - Day 3

Third day of Bruegel Annual Meetings.

Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: September 3, 2020
Read about event
 

Past Event

Past Event

Bruegel Annual Meetings 2020 - Day 2

Second day of Bruegel Annual Meetings.

Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: September 2, 2020
Read about event
 

Past Event

Past Event

Bruegel Annual Meetings 2020 - Day 1

The Annual Meetings are Bruegel's flagship event which gathers high-level speakers to discuss the economic topics that affect Europe and the world.

Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: September 1, 2020
Read article More on this topic
 

Blog Post

Emerging market central banks and quantitative easing: high-risk advice

Central banks in emerging markets with weak currencies should not resort to unorthodox monetary tools such as quantitative easing as a response to the crisis triggered by COVID-19. Preferable alternatives include shifting public spending away from less pressing needs, moderately increasing public debt and falling back on official development assistance.

By: Marek Dabrowski and Marta Domínguez-Jiménez Topic: Global Economics & Governance Date: August 26, 2020
Read article More on this topic More by this author
 

Opinion

Coronavirus recovery: invest rainy day savings to boost Hong Kong’s economy

The Hong Kong government might want to consider diversifying its economy by using part of the savings earmarked for rainy days. Beyond cushioning the negative impact of Covid-19 on SMEs and households, it is one more reason to spend.

By: Alicia García-Herrero Topic: Global Economics & Governance Date: August 6, 2020
Read article More on this topic More by this author
 

Opinion

The Challenges of the Post-Pandemic Agenda

This opinion piece has previously been published in Project Syndicate. PARIS – There is a growing possibility that the COVID-19 crisis will mark the end of the growth model born four decades ago with the Reagan-Thatcher revolution, China’s embrace of capitalism, and the demise of the Soviet Union. The pandemic has highlighted the vulnerability of […]

By: Jean Pisani-Ferry Topic: Global Economics & Governance Date: July 28, 2020
Read article More on this topic
 

Opinion

Can households in the European Union make ends meet?

Half the households surveyed by Eurostat see themselves as unable to find the resources they would need to cope with an unexpected expense within a month, estimated by experts at €375 in the case of Greece.

By: Maria Demertzis, Marta Domínguez-Jiménez and Annamaria Lusardi Topic: Finance & Financial Regulation Date: July 24, 2020
Read article More on this topic More by this author
 

Blog Post

Having the cake, but slicing it differently: how is the grand EU recovery fund allocated?

The European Commission’s original allocation mechanism really favoured lower-income countries and to a large extent was based on pre-COVID economic data. The modification adopted by the European Council gives more consideration to the country size and the adverse economic impact of COVID-19. As a consequence, by using the Commission’s May 2020 economic forecasts, I estimate that only Germany and France will get more grants from the EU’s recovery fund compared to the Commission’s original proposal, while other countries will get less.

By: Zsolt Darvas Topic: European Macroeconomics & Governance Date: July 23, 2020
Read article More on this topic
 

Blog Post

Government-guaranteed bank lending: beyond the headline numbers

Loan guarantees have been a major part of the COVID-19 support packages offered by European governments to companies. The actual take-up numbers so far follow very different patterns from the headline announcements, and might allay early concerns about single market distortions caused by the different sizes of packages in different countries.

By: Julia Anderson, Francesco Papadia and Nicolas Véron Date: July 14, 2020
Load more posts